Article
Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes.
Pharmacogenomics - 1 Oct 2023
Koon Alexis, He Jiaxian, Patel Jai, Morse Allison, Boseman Victoria, Hamilton Alicia, Knight Thomas, Shah Nilay, Ragon Brittany, Chojecki Aleksander, Ai Jing, Steuerwald Nury, Gerber Jonathan, Copelan Edward, Grunwald Michael, Arnall Justin
Abstract excerpt
Intravenous pentamidine is used for prophylaxis against Pneumocystis jirovecii pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by CYP2C19, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as P. jirovecii pneumonia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.